
Regulatory
12 days ago
FDA Approves Johnson and Johnson’s CaplytaLatest Content

Johnson and Johnson Acquiring Halda Therapeutics in $3 Billion Definitive Agreement

How the FDA Commissioner’s National Priority Vouchers Reshape Manufacturing, Pricing & Global Strategy

Pharmaceutical Executive Daily: Novo Nordisk's Leadership Restructure

Scott Gottlieb to Join UnitedHealth Board of Directors

Novo Nordisk Rolls Out $199 Intro Offer for Wegovy and Ozempic, Months Ahead of Planned Price Cuts

Shorts










Podcasts
Videos
All News

Eli Lilly partners with ABL Bio to research innovative therapeutics and expand its portfolio in cancer and CNS diseases through advanced bispecific antibody technology.

Start managing the transformation now to secure every benefit.

Jay Lalezari, CEO, CytoDyn, emphasizes how regulatory T cells play a crucial role in tumor progression by enabling cancers to evade immune detection.

Novo Nordisk’s board overhaul signals a decisive return to Foundation-led scientific and operational governance, raising strategic questions about whether the company can sustain U.S. growth and consumer-market leadership in the GLP-1 era without deeper American commercial expertise.

Olympia Pharmaceutical’s CEO discusses the company’s expansion into Mississippi.

A Q&A with Christopher Stanton, Ph.D., Marvin Bower Associate Professor of Business Administration at Harvard Business School.

Dr. Jaspal Singh explains some of the barriers that prevent cancer patients from getting biomarker testing early in their treatment journey.

Craig Ackerman, partner in the Alexander Group and lead of its medical device practice, explains the differences in strategy based on which region you’re strategizing for.

The agreement brings Cidara’s potential flu vaccine under Merck’s umbrella.

The nationally licensed pharmacy network now supports Ethereum, Solana, and XRP across all retail locations, marking a major step toward faster, more transparent payments—and laying the groundwork for a blockchain-based prescription drug payment system.

Approval of Komzifti (ziftomenib) provides a new targeted option for a high-risk patient population and strengthens the Kura Oncology–Kyowa Kirin collaboration, which includes a global development and commercialization strategy.

In today’s Pharmaceutical Executive Daily, WeightWatchers plans to offer Novo Nordisk’s oral Wegovy pending FDA approval, FDA unveils a new Plausible Mechanism Pathway to accelerate drug reviews, and Ovid Therapeutics and Metagenomi share key third-quarter results and leadership changes.

Craig Ackerman, partner in the Alexander Group and lead of its medical device practice, discusses how events from the past few years have shaped the current market.

eClinical Solutions' chief delivery officer highlights challenges and opportunities for innovation and health equity.

Jay Lalezari, CEO of CytoDyn, explains how the CCR5 receptor has emerged as a pivotal target in metastatic cancers due to its dual role in promoting tumor cell migration and shaping a protective tumor microenvironment.























